Company Announcements

Board Change Update

Source: RNS
RNS Number : 0622K
Diaceutics PLC
29 October 2024
 

Diaceutics PLC - Board Change Update


Belfast and London, 29 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces that following the announcement on 1 October 2024 and completion of the usual Nominated Adviser due diligence checks, Cheryl MacDiarmid is confirmed as having joined the board as a Non-Executive Director.

 

The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:

 

Additional information with regard to Cheryl MacDiarmid:

Cherly MacDiarmid (née Gaskin), age 56, is currently or has been a director of the following companies within the past five years:

 

 

Current Directorships

Former Directorships

Allergy Therapeutics Plc



Phivco UK Limited


ViiV Healthcare UK (NO.6) Limited


ViiV Healthcare UK (NO.3) Limited


ViiV Healthcare UK (NO.5) Limited


ViiV Healthcare Trading Services UK Limited


ViiV Healthcare UK (NO.4) Limited


ViiV Healthcare Overseas Limited


ViiV Healthcare UK (NO.7) Limited


ViiV Healthcare Finance Limited


ViiV Healthcare UK Limited


Phivco UK II Limited

 

 

Enquiries:

Diaceutics PLC  


Ryan Keeling, Chief Executive Officer 

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com



Canaccord Genuity Limited (Nomad & Broker)

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees


 

Alma Strategic Communications

 

Tel: +44(0)20 3405 0205

Caroline Forde, Kinvara Verdon

diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFEMFSUELSEES